Medical Experts criticize Turing Pharmaceuticals’ decision to raise Daraprim’s Price
Medical Experts criticize Turing Pharmaceuticals’ decision to raise Daraprim

Earlier, Turing Pharmaceuticals announced that it has hiked price of toxoplasmosis treatment drug Daraprim. The price was hiked after the drug was acquired by Turing Pharmaceuticals in August this year. Now, physicians and doctors are crying foul about the company's decision to sell a tablet for about $760.

Health experts are saying that the price hike may prevent poor people with toxoplasmosis from getting the drug, but Martin Shkreli, owner of Turing Pharmaceuticals, said the price hike wouldn't affect poor patients. Turing has been working to make a 'fair profit' that will help the company invent a new medication to treat the parasite that troubles pregnant women, cancer patients and individuals with weakened immune systems, Shkreli added.

Physician and doctor groups are not the only ones criticizing Turing's decision, Democratic presidential candidate Hillary Clinton has also said 'price gouging' by Turing was unfair.

Daraprim got approval from the United States Food and Drug Administration in 1953. A recently written letter by IDSA and HIVMA said that the drug could cost as much as $634,500 per year. The new cost of the drug is unjustifiable for the medically vulnerable patients in need and unsustainable for the country's health care system, according to the letter.

"This cost is unjustifiable for the medically vulnerable patient population in need of this medication and unsustainable for the health care system", the letter said. The experts cited the inclusion of toxoplasmosis in the list of five neglected parasitic diseases of the Centers for Disease Control and Prevention (CDC).